A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
Key facts
- Where
- Brampton, Burlington, Calgary, Concord, Courtice, Edmonton, Etobicoke, Greater Sudbury, Hamilton, Joliette, Lévis, London, Mirabel, Mississauga, Moncton, Montreal, Nepean, New Westminster, Ottawa, Pointe-Claire, Québec, Sarnia, Sherbrooke, Terrebonne, Toronto, Trois-Rivières, Victoriaville, and Winnipeg, CanadaSee the 39 sites
- Phase
- Phase 4
Where in Canada
- Centricity Research Brampton EndocrinologyBrampton, CanadaTaking people
- Centricity Clinical Research BurlingtonBurlington, CanadaNo longer taking part
- Centricity Research Calgary EndocrinologyCalgary, CanadaTaking people
- Centricity Research Vaughn EndocrinologyConcord, CanadaTaking people
- Medical Trust Clinics, Inc.Courtice, CanadaNo longer taking part
- Alta Clinical Research at Hermitage MedicentreEdmonton, CanadaTaking people
- Centricity Research Etobicoke EndocrinologyEtobicoke, CanadaTaking people
- Janik ResearchGreater Sudbury, CanadaTaking people
- Hamilton Medical Research GroupHamilton, CanadaTaking people
- Diex Recherche (Joliette)Joliette, CanadaTaking people
- Alpha Recherche Clinique - Clinique de LevisLévis, CanadaTaking people
- St. Josephs Health CareLondon, CanadaTaking people
- Western Univ. Cnt for Studies in Fam MedLondon, CanadaTaking people
- Centricity Research MirabelMirabel, CanadaTaking people
- Malton Medical ClinicMississauga, CanadaNo longer taking part
- G.A. Research Associates, Ltd.Moncton, CanadaTaking people
- Applied Medical Informatics ResearchMontreal, CanadaTaking people
- Centre Hospitalier de l'Université de MontréalMontreal, CanadaNot yet recruiting
- Clinique Endocrinologie OASIS.Montreal, CanadaTaking people
- McGill University Health CentreMontreal, CanadaNot yet recruiting
- Centricity Research Ottawa LMCNepean, CanadaTaking people
- Fraser Clinical Trials, Inc.New Westminster, CanadaTaking people
- The Ottawa Hospital_RiversideOttawa, CanadaNot yet recruiting
- Centricity Res Pointe-ClairePointe-Claire, CanadaTaking people
- Alpha Recherche Clinique - LebourgneufQuébec, CanadaTaking people
- Centre de Recherche Saint-LouisQuébec, CanadaTaking people
- Diex Recherche QuébecQuébec, CanadaTaking people
- Recherche Clinique Sigma incQuébec, CanadaTaking people
- Alpha Recherche CliniqueQuébec, CanadaNo longer taking part
- Bluewater Clin Res Group IncSarnia, CanadaNo longer taking part
- Centre de Recherche Saint-LouisSherbrooke, CanadaTaking people
- Diex Recherche SherbrookeSherbrooke, CanadaNo longer taking part
- Ctr de Med Metab de LanaudiereTerrebonne, CanadaTaking people
- Centricity Research TorontoToronto, CanadaTaking people
- Sewa Ram Singal Medicine Professional CorpToronto, CanadaTaking people
- Centricity Research Toronto Manna MultispecToronto, CanadaNo longer taking part
- Diex Recherche Trois-RivieresTrois-Rivières, CanadaTaking people
- Diex Recherche VictoriavilleVictoriaville, CanadaTaking people
- Winnipeg ClinicWinnipeg, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07112339EU 2024-520068-32-00
- Record updated
- 11 August 2026
- Original description
This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for the treatment of type 2 diabetes. The study will last for about 13 months.Read full original descriptionShow less
EFFectiveness of Once-weekly Insulin ICodec Versus Once-daily Basal Insulin Analogues in an Insulin-naïve Type 2 diabEtes Population in Real-world cliNical pracTice- The EFFICIENT Pragmatic Study Effectiveness of Insulin Icodec in Real-world Clinical Practice
This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for the treatment of type 2 diabetes. The study will last for about 13 months.
Inclusion: Diagnosed with T2D greater than or equal to (≥) 180 days prior to the day of screening; Treatment with any of the following non-insulin glucose-lowering medication(s) or combination regimen(s) at the time of screening:; Metformin, Sulfonylureas, Meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, Thiazolidinediones, Alpha-glucosidase inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs), Oral or injectable glucagon-like peptide-1 (GLP-1) receptor agonists and Injectable dual glucose-dependent insulinotropic polypeptides (GIP) and GLP-1 receptor agonist; Need of intensification with basal insulin, as indicated at the discretion of the investigator; Recorded HbA1c value ≥7% within the last 90 days prior to randomization.
Exclusion: Previous participation in this study. Participation is defined as signed informed consent; Participation (i.e., received any study intervention) in any interventional clinical study within 90 days before screening; Known or suspected hypersensitivity to study intervention(s) or related products; Any disorder which in the investigator's opinion might jeopardize participant's safety; Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method.